Yes, to the extent that the rejection on efficacy isn't tied to issues of manufacturing quality and batch consistency, one could be approved and not the other.
But if it's manufacturing and batch consistency that MSB doesn't have "right" for AGVHD, then those same issues apply to Rem-L for COVID.
Sorry, argued my point too broadly!
- Forums
- ASX - By Stock
- MSB
- FDA ODAC Meeting Material discussion analysis
FDA ODAC Meeting Material discussion analysis, page-352
-
- There are more pages in this discussion • 140 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.47 |
Change
0.015(1.03%) |
Mkt cap ! $1.684B |
Open | High | Low | Value | Volume |
$1.46 | $1.49 | $1.44 | $2.838M | 1.945M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 26369 | $1.46 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.47 | 18825 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 21042 | 1.470 |
7 | 25592 | 1.465 |
11 | 71764 | 1.460 |
10 | 85845 | 1.455 |
4 | 24055 | 1.450 |
Price($) | Vol. | No. |
---|---|---|
1.480 | 131643 | 22 |
1.485 | 156054 | 16 |
1.490 | 114332 | 14 |
1.495 | 69042 | 8 |
1.500 | 160546 | 16 |
Last trade - 14.51pm 21/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online